Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bendamustine and rituximab with or without acalabrutinib in previously untreated mantle cell lymphoma
RBR-2xt4ykPhase 3Recruiting
- Sponsor
- Hospital São Rafael
- Start
- Nov 2017
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of acalabrutinib, bendamustine, rituximab in mantle cell lymphoma (MCL), sponsored by Hospital São Rafael. Started Nov 2017; status: recruiting.
02
Drugs
acalabrutinibbendamustinerituximab
03
Conditions
mantle cell lymphoma (MCL)
Beyond the preview
Go deeper on RBR-2xt4yk.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on RBR-2xt4yk.